Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Crispr Therapeutics Ag (NQ: CRSP )

45.32 -1.66 (-3.53%)
Streaming Delayed Price Updated: 11:36 AM EDT, Oct 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

All News about Crispr Therapeutics Ag

< Previous 1 2 3 4 5 6 7 8 9
...
29 30 Next >
Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit.
Pfizer stock dipped Thursday after the company voluntarily pulled its sickle cell drug, Oxbryta, from the market following patient deaths. 
Via Investor's Business Daily
3 Dirt Cheap Stocks to Buy Right Now
Bargain hunters should love these great stocks. 
Via The Motley Fool
Down 21% This Year, Is CRISPR Therapeutics Stock Still a Buy?
There's a lot of growth on the way, and soon. 
Via The Motley Fool
1 Biotech Stock Down 62% to Buy and Hold
It's an excellent opportunity to buy shares of what could become a biotech giant on the dip. 
Via The Motley Fool
3 No-Brainer Biotech Stocks to Buy With $200 Right Now
An investment in these players today could score a big win down the road. 
Via The Motley Fool
Looking for Stock Bargains With Room to Run? Try This.
Investing tips from Bill Mann, The Motley Fool's director of small-cap research. 
Via The Motley Fool
Down Nearly 50% From Its 52-Week High, Is CRISPR Therapeutics a Steal of a Deal?
Is the potential upside for CRISPR Therapeutics too massive to ignore? 
Via The Motley Fool
3 Monster Biotech Stocks to Buy Before 2025
These companies are nearly in the sweet spot of risk versus reward in biotech. 
Via The Motley Fool
Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030
The companies are chasing major innovations. 
Via The Motley Fool
Got the Market Sell-Off Blues? Do These 3 Things Right Now
You aren't powerless in the face of what the market throws at you. 
Via The Motley Fool
Jim Cramer: This Energy Stock Is A Buy, Stay Away From DexCom
The "Mad Money" host says Dexcom had "a real bad miss... they still really haven't fully explained why that is." 
Via Benzinga
7 Biotech Stocks to Buy for Their Game-Changing Potential
Although the market may be reeling from the recent fallout, the red ink presents a viable opportunity in these biotech stocks. 
Via InvestorPlace
The 3 Best Gene Editing Stocks to Buy in August 2024
These are the best gene-editing stocks to buy as the biotechs pursue precision therapies to cure rare diseases. 
Via InvestorPlace
Is It Too Late to Buy Vertex Pharmaceuticals Stock?
Shares of the rare disease drugmaker are already up more than 40% over the past year. 
Via The Motley Fool
CRSP Stock Earnings: CRISPR Therapeutics Beats EPS, Misses Revenue for Q2 2024
CRSP stock results show that CRISPR Therapeutics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
Via InvestorPlace
Prediction: These Could Be the Best-Performing Growth Stocks Through 2030
Great companies are found in every type of market landscape. 
Via The Motley Fool
Prediction: CRISPR Therapeutics Stock Could Be a Millionaire-Maker
The biotech recently became a commercial-stage company. 
Via The Motley Fool
3 Unstoppable Stocks to Buy in August
It's not hard to envision how all three of these stocks can deliver exceptional growth. 
Via The Motley Fool
10 Best Small and Mid-Cap Stocks to Consider Buying in August
A shift in market dynamics could favor these 10 growth stocks. 
Via The Motley Fool
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The strugglingh stock investor did a little bit of shopping on Tuesday, adding to some of her existing positions. 
Via The Motley Fool
The Top 3 Cathie Wood Stocks to Buy Now: Summer 2024
The investing guru likes to take the pulse of where the world will be tomorrow and these Cathie Wood stocks reflect that vision. 
Via InvestorPlace
3 Small-Cap Stocks to Buy at a 52-Week Low
The Russell 2000 is hinting at sector rotation, meaning it’s time for bargain hunters to look for small-cap stocks at 52-week lows 
Via InvestorPlace
3 Gene Editing Stocks Shaping the Future of Medicine
Gene editing stocks offer a bold venture into biopharma's future, leveraging CRISPR technology for transformative healthcare solutions 
Via InvestorPlace
3 Monster Stocks in the Making to Buy Right Now
They're small now, but these stocks could grow much larger. 
Via The Motley Fool
3 Gene Editing Stocks That Could Grow Your Wealth
Investors looking for gene editing stocks of cutting edge technology firms should consider these biotech stocks. 
Via InvestorPlace
3 Gene-Editing Stocks That Could Be Multibaggers in the Making: July Edition
Explore gene-editing stocks with potential to become multibaggers as the industry advances in treating genetic disorders. 
Via InvestorPlace
Blue Chips, Small Caps Extending Their Breakout
The Dow Jones Industrial Average is stealing the show today, last seen up 546 points for a new record high and on track for its best single-session gain since January 2023. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
CRISPR Therapeutics could start reporting product revenue soon. 
Via The Motley Fool
1 Biotech Stock to Buy Hand Over Fist and 1 to Avoid
These two stocks could have vastly different long-term performances. 
Via The Motley Fool
Cathie Wood Touts Palantir, Coinbase And Roku As ARK's Flagship Fund Shifts Focus From Mag 6 Amid 'Whiff' Of Lower Interest Rates
In a recent letter to investors, Cathie Wood, the CEO of ARK Invest, highlighted the potential of the company's flagship fund, ARK Innovation ETF, despite its recent underperformance. 
Via Benzinga
Topics ETFs
< Previous 1 2 3 4 5 6 7 8 9
...
29 30 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.